A retrospective study of 30 cases evaluating the efficacy and safety of anlotinib plus Temozolomide for recurrent/residual glioma from a single center.

BMC Cancer · 2025 · PMC12541956 · PMID 41126110

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For example, older age (> 55 years) was associated with an increased risk of death (HR = 2.15, 95% CI: 0.67–6.91) and progression (HR = 2.53, 95% CI: 0.75–8.47), while IDH mutation showed a trend toward reduced risk of death (HR = 0.34, 95% CI: 0.08–1.46).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.